1. Home
  2. SPRO vs SORA Comparison

SPRO vs SORA Comparison

Compare SPRO & SORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$0.94

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo Top Win International Limited Ordinary Shares

SORA

Top Win International Limited Ordinary Shares

SELL

Current Price

$2.40

Market Cap

56.7M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
SPRO
SORA
Founded
2013
2001
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
56.7M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
SPRO
SORA
Price
$0.94
$2.40
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $5.33
N/A
AVG Volume (30 Days)
★ 320.0K
13.4K
Earning Date
11-12-2026
04-30-2027
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
N/A
EPS
N/A
★ N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.24
N/A
52 Week Low
$0.95
$1.25
52 Week High
$3.08
$4.49

Technical Indicators

Market Signals
Indicator
SPRO
SORA
Relative Strength Index (RSI) 34.32 51.86
Support Level N/A $1.99
Resistance Level $1.27 $2.56
Average True Range (ATR) 0.06 0.10
MACD -0.01 -0.01
Stochastic Oscillator 3.18 77.50

Price Performance

Historical Comparison
SPRO
SORA

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SORA Top Win International Limited Ordinary Shares

AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.

Share on Social Networks: